CYT News

The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL) priced at the midpoint to raise $425 million at a $4.7 billion market cap. The company is using proprietary genetic and...read more

Cyteir Therapeutics, an early stage oncology biotech developing small molecule therapies that inhibit DNA damage repair, raised $133 million by offering 7.4 million shares at $18, the high end of the range of $16 to $18. Cyteir Therapeutics' lead candidate, CYT-0851, is a novel, oral small molecule inhibitor of homologous recombination, a DNA repair pathway critical for the...read more

Cyteir Therapeutics, an early stage oncology biotech developing small molecule therapies that inhibit DNA damage repair, announced terms for its IPO on Monday. The Lexington, MA-based company plans to raise $126 million by offering 7.4 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Cyteir Therapeutics would command a fully diluted market...read more

Updated Monday, 6/14. 15 IPOs are currently slated to raise $2.5 billion in the week ahead, led by a preclinical biotech being valued at $4.7 billion. The largest deal of the week, Lyell Immunopharma (LYEL) plans to raise $425 million at a $4.7 billion market cap. The company is using proprietary genetic and epigenetic reprogramming to develop T...read more